Additionally, we applied tissue microarrays (TMAs) of RCC samples and immunohistochemistry (IHC) analyses to evaluate the correlation between the expression of CD151 and clinicopathologic characteristics of RCC patients. This evidence concerns the gene CD151 and renal cell carcinoma.